Research of Anti-tumor Immune Responses to Gastrointestinal (GI) Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 180

Special Issue Editor

E-Mail Website
Guest Editor
1. Department of Gastroenterology and Hepatology, Asahi University Hospital, Gifu 500-8523, Japan
2. Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
Interests: immunotherapy; immune checkpoint inhibitors; endogenous tumor antigen; cytokine profiling; immune-radiation therapy; adoptive cell therapy

Special Issue Information

Dear Colleagues,

New treatments such as immune checkpoint inhibitor, molecular-targeted agent, and antibody drug conjugate, developed for GI cancer, result in improving patient’s outcome in the last decade. We believe that deep insight into the tumor immunological background of GI cancer will develop novel combination immunotherapy. Moreover, analyzing molecular background by gene panel testing using next-generation sequencer and then appropriate patient’s selection are essential for the development of combination immunotherapy. Based on tumor immunology, Special Issue will highlight recent important and promising research for making breakthrough in immunotherapy for GI cancer.

Dr. Naoyuki Sakamoto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • immuno-oncology
  • immune checkpoint blockade
  • tumor immune microenvironment
  • combination immunotherapy
  • precision medicine
  • targeted therapy

Published Papers

This special issue is now open for submission.
Back to TopTop